Long-term risk of ischemic stroke associated with rofecoxib

Cardiovascular Drugs and Therapy

Volumn 21, Issue 2, 2007, Pages 117-120

  Afilalo, Jonathan ^a   Coussa Charley, Michael J ^a   Eisenberg, Mark J ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b Quebec Foundation for Health Research   (Canada)

Author keywords

Cerebrovascular accident; Cox 2 inhibitor; Rofecoxib; Stroke

Indexed keywords

PLACEBO; ROFECOXIB;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLON POLYP; COLORECTAL CANCER; CONFIDENCE INTERVAL; DRUG EFFECT; DRUG WITHDRAWAL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; INCIDENCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADENOMATOUS POLYPS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LACTONES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RISK; SULFONES; TIME FACTORS;

EID: 34249680833     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6011-9     Document Type: Article

References (18)

1. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
2. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005;142:481-9.
3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8, 2.
4. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9.
5. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8.
6. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-8.
7. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
8. Merck. APPROVe extension statistical package. http://www.merck.com/ newsroom/vioxx_withdrawal/pdf/APPROVe_Extension_Statistical_Package.pdf. 26-5-2006. 4-7-2006.
9. Andersohn F, Schade R, Suissa S, Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 2006;37:1725-30.
10. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-7.
11. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11.
12. FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879-90.
13. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 2000;14:83-90.
14. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165:490-6.
15. Fosslien E. Cardiovascular complications of non-steroidal anti-inflammatory drugs. Ann Clin Lab Sci 2005;35:347-85.
16. Bogaty P, Brophy JM, Noel M, Boyer L, Simard S, Bertrand F, Dagenais GR. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. Circulation 2004;110:934-9.
17. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005;30:1204-15.
18. Lagakos SW. Time-to-event analyses for long-term treatments-the APPROVe trial. N Engl J Med 2006;355:113-7.